• 40岁的她靠晒这张照片上热搜 2019-07-17
  • 图解:关于世界杯开幕式的那点事 2019-07-17
  • 女性之声——全国妇联 2019-06-23
  • 人民网旅游3·15投诉平台--旅游频道 2019-06-20
  • 2018中国双一流大学专业排行榜发布 清华大学位列第一 2019-06-20
  • 今天,首艘国产航母下水!这六大方面信息你得掌握 2019-06-16
  • 央行金融市场流动性合理稳定 经济金融运行平稳 2019-06-14
  • 【理上网来·辉煌十九大】 2019-05-11
  • 中华龙舟如何奋楫争先?习近平这些话要牢记 2019-04-12
  • 楼市调控重点转向三四线城市 释放什么信号? 2019-04-12
  • 国家行政学院中国领导科学研究中心副秘书长雷强做客人民网 2019-04-11
  • 新华时评:不忘初心 向善前行 2019-04-05
  • 对话国家体育总局副局长高志丹 2019-03-30
  • 岚山区:婚育新风吹进基层 2019-03-30
  • 停止接客!杭州奥体某盘摇号在即 购房者头顶烈日前往 ——凤凰网房产 2019-03-29
  • 第一金融网主办
    »您现在的位置: 第一金融网 >> 金融焦点 >> 文传商讯 >> 正文

    Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

    2019/7/3 10:19:26  文章来源:文传商讯  作者:文传商讯
    文章简介: BoehringerIngelheimfocusesonthedevelopmentofnextgenerationNASHtreatmentsthattargetallthreekeydriversofthedisease-steatosis,inflammation

    电子游戏 www.hpqjf.com Boehringer Ingelheim focuses on the development of next generation NASH treatments that target all three key drivers of the disease - steatosis, inflammation and fibrosis
    Collaboration aims to develop first-in-class dual agonist (GLP1R/FGF21R agonist) for NASH
    Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties

    INGELHEIM, Germany & SEOUL, South Korea -- (BUSINESS WIRE) --

    Boehringer Ingelheim and Yuhan Corporation today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. The collaboration brings together Yuhan Corporation’s expertise in FGF21 biology, obesity and NASH with Boehringer Ingelheim’s pharmaceutical expertise and commitment to bringing innovative medicines to patients with cardiometabolic diseases.

    NASH often starts with the accumulation of fat in the liver, giving rise to inflammation and finally leading in many patients to liver fibrosis and cirrhosis. It has an especially high prevalence among obese and diabetic patients and is an area of high-unmet medical need with no treatments currently available. Boehringer Ingelheim believes that in many cases approaches targeting one of the features of NASH will not be able to achieve the desired resolution of NASH in patients with advanced stages of the disease. Thus Boehringer Ingelheim has built a comprehensive program to develop next generation therapy approaches targeting all three key drivers of the disease - steatosis, inflammation and fibrosis.

    Preclinical evidence suggests high efficacy, when combining the gut-derived hormone GLP-1 with FGF21. The dual agonist (GLP1R/FGF21R agonist) is expected to reduce liver cell injury and hepatic inflammation by resolution of steatohepatitis as well as having direct antifibrotic effects and complements Boehringer Ingelheim’s R&D portfolio in NASH adding another potential first-in-class opportunity.

    “We are excited about this new opportunity which adds to our longstanding and successful partnership with Yuhan Corporation,” says Dr. Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the Innovation Unit. “This partnership brings us closer to next generation treatments for patients with NASH,” adds Pairet.

    ”We look forward to working jointly with Boehringer Ingelheim, with its strong track record of bringing new treatments to patients with cardiometabolic disease. Boehringer Ingelheim’s clinical expertise will now be applied to the development of this drug which has the potential to make a real difference for patients with NASH,” says Jung Hee Lee, CEO and President at Yuhan Corporation. “This molecule, which is a fusion protein utilizing the long-acting (HyFc) technology of Genexine, has been developed in-house by Yuhan Corporation. Not only is our collaboration with Boehringer Ingelheim on this molecule Yuhan’s first external partnership with biologics, it is also the very first out-licensing of biologics targeting NASH from Korea,” adds Mr. Lee.

    Boehringer Ingelheim has a long history of excellence in the discovery and development of medicines for patients with cardiometabolic diseases. It has established a broad portfolio of marketed products for thromboembolic diseases, type 2 diabetes, acute myocardial infarction, hypertension, and cardio-renal risk reduction. The cardiometabolic diseases pipeline extends beyond type 2 diabetes and anticoagulation with a focus on innovative drugs for the treatment of the devastating consequences of diabetes as well as contributing factors like obesity.

    Yuhan Corporation has over many years been a commercial partner for selected Boehringer Ingelheim cardiovascular and metabolic products in Korea. Under the terms of the agreement Yuhan Corporation will receive an upfront and near term payments of USD 40 million and is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.

    Please click on the link for “Notes to the Editors”:
    //www.boehringer-ingelheim.com/press-release/collaboration-yuhan-corporation-nash

    View source version on businesswire.com: https://www.businesswire.com/news/home/20190701005465/en/

    CONTACT:

    Media Contacts:
    Boehringer Ingelheim
    Dr. Reinhard Malin
    Head of Communications Innovation Unit
    Boehringer Ingelheim Corporate Center GmbH
    Media + PR
    P: +49 6132 77-90815
    [email protected]

    Linda Ruckel
    Associate Director, Media and Corporate Reputation
    Boehringer Ingelheim U.S.
    Media + PR
    P: + 203-791-6672
    [email protected]

    Yuhan Corporation
    Investors:
    Jaehong Park
    Head of Investor Relations Team
    +82 2-828-0265

    Media:
    Jongwon Kim
    Manager, Public Relations Team
    +82 2-828-0036

    分享到:
    第一金融网免责声明:
    1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
    2、文章来源为均为其它媒体的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供更多信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
    3、本网站所载文章、数据、网友投稿等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一金融网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
    发表评论

    【发表评论】(网友评论内容只代表网友观点,与本站立场无关?。?/td>
     姓 名:
     评 分: 1分 2分 3分 4分 5分
     评论内容:
    验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  葛洲坝电力被拉黑背后:高层调整,有项目分包商
     中国“神船”来了 南船北船拟重组将成市值最高造
    [银行]  招行交行浦发齐发声:未受到相关制裁调查
     央行:55万户中小微企业获信贷支持,贷款余额11
    [股票]  提速!证监会一天同意7家公司科创板IPO注册 一文
     官宣了!两大造船集团拟重组"中国神船"即将出世
    [基金]  大盘重回3000点 大涨底气在哪?基金最新解读来了
     A股酝酿变盘信号!公募逆势加仓,北上资金调仓换
    [保险]  人保车险理赔时间规定
     职工医保和新农合医保哪个好?主要看这三点
    [期货]  大跌4%!油价快到50美元 这是个让美国尴尬的位置
     国际油价连续破位下跌 原油类QDII净值“很受伤”
    [股评]  券商评级:三大股指全线收阳 九股迎掘金良机
     波司登第三次“回怼”做空机构报告 股价继续反弹
    [港股]  二次上市回到香港 阿里和港交所将得到什么?
     小米"成长的烦恼":股价几近腰斩 主营亟待破局
    [美股]  苹果召回部分MacBook Pro笔记本电脑 存在“火灾
     2019京东618销售成绩单出炉
    [外汇]  贸易战犹如高悬在人民币头顶的达摩克利斯之剑 落
     央行喊话!潘功胜霸气强调"完全有能力保持汇市稳
    [债券]  中国债市:隔夜回购创近十年新低
     施罗德投资:6月全球债市进入避险模式
    [黄金]  刘智辛:欧美货币持稳,黄金日线三连阳,原油多
     央行连续4个月耗资120亿元爆买黄金!全球都在买
    [理财]  郭美美将刑满释放 回想她炫富的样子 仿佛就在昨
     炎夏养生须谨记:一觉、二瓜、三汤、四穴、五果
    [信托]  跌破8% 集合信托收益或继续下跌
     信托违约增多 预期收益9%的产品还能买吗?
    [房产]  251次破纪录: 三维解读上半年楼市调控政策
     二三线城市争建摩天大楼 天际线下暗藏风险
    [汽车]  北京市实施“国六”机动车排放标准首日见闻
     7月重磅新规实施!2019车辆购置税按裸车价交税
  • 此栏目下没有推荐文章
  • | 设为首页 | 加入收藏 | 关于我们 | 友情链接 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2027 电子游戏 All Rights Reserved 版权所有·电子游戏 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以电子游戏名义做股票推荐的行为均属违法!

    广告商的言论与行为均与电子游戏无关!股市有风险,投资需谨慎。

    合作邮箱:电子游戏 合作电话:18678839953 点击这里给我发消息

  • 40岁的她靠晒这张照片上热搜 2019-07-17
  • 图解:关于世界杯开幕式的那点事 2019-07-17
  • 女性之声——全国妇联 2019-06-23
  • 人民网旅游3·15投诉平台--旅游频道 2019-06-20
  • 2018中国双一流大学专业排行榜发布 清华大学位列第一 2019-06-20
  • 今天,首艘国产航母下水!这六大方面信息你得掌握 2019-06-16
  • 央行金融市场流动性合理稳定 经济金融运行平稳 2019-06-14
  • 【理上网来·辉煌十九大】 2019-05-11
  • 中华龙舟如何奋楫争先?习近平这些话要牢记 2019-04-12
  • 楼市调控重点转向三四线城市 释放什么信号? 2019-04-12
  • 国家行政学院中国领导科学研究中心副秘书长雷强做客人民网 2019-04-11
  • 新华时评:不忘初心 向善前行 2019-04-05
  • 对话国家体育总局副局长高志丹 2019-03-30
  • 岚山区:婚育新风吹进基层 2019-03-30
  • 停止接客!杭州奥体某盘摇号在即 购房者头顶烈日前往 ——凤凰网房产 2019-03-29
  • 孩子玩电子游戏的危害 腾讯全民突击 七乐彩中奖规则表 76人所 湖北楚天风彩30选5开奖 奥格斯堡vs多特蒙德历史 布莱顿英超赛程 北京pk10开奖时间 十一运夺金走势图 海南麻将单机版 北京赛车计划网站3码 天津时时彩五星组选60 中超官网中超足球 七星彩走势图综合版最近200期 我的世界mod 刀塔自走棋图鉴